8 posts
GSK has been making headlines recently with its $10.6 billion acquisition of Nuvalent, a U.S.-based cancer drugmaker. This deal caught my attention because it represents a signifi...
When I stumbled upon the news of Immunic naming Erik Lundgren as CEO, it caught my attention. The company is advancing its Phase 3 trials in multiple sclerosis MS, a disease that'...
GSK caught my attention today due to a couple of recent developments that have stirred the pot for this pharmaceutical giant. The company's new drug, efimosfermin, has received re...
I’ve been keeping an eye on CE lately, especially after Roche received CE approval for their Elecsys ApoE4 biomarker test. This approval could be a significant catalyst for the co...
General Electric GE has been capturing attention lately, not least because of some recent developments that could have significant implications for its future. GE HealthCare just...
Johnson & Johnson JNJ caught my eye today, not just because it's a household name, but because it's been getting a lot of buzz for its reliability and potential to anchor a retirem...
Global Partners LP GLP caught my attention today because of recent developments involving the FDA's crackdown on GLP-1 pills. Hims & Hers Health, a company that had been offering...
Eli Lilly LLY has been grabbing attention lately, not just for its massive market cap of nearly $949 billion, but also due to some pretty impressive growth projections. Analysts a...